Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study

Letermovir (LMV) is a new antiviral drug used to prevent cytomegalovirus infection in hematopoietic stem cell transplantation (HSCT) recipients. It has been reported to increase tacrolimus (TAC) exposure and decrease voriconazole (VRCZ) exposure in healthy participants. However, VRCZ inhibits the me...

Descripción completa

Detalles Bibliográficos
Autores principales: Hikasa, Shinichi, Shimabukuro, Shota, Osugi, Yuko, Ikegame, Kazuhiro, Kaida, Katsuji, Fukunaga, Keiko, Higami, Tomoko, Tada, Masami, Tanaka, Kuniyoshi, Yanai, Mina, Kimura, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163365/
https://www.ncbi.nlm.nih.gov/pubmed/32308538
http://dx.doi.org/10.7150/ijms.42011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163365/
https://www.ncbi.nlm.nih.gov/pubmed/32308538
http://dx.doi.org/10.7150/ijms.42011

Ejemplares similares